12.2.2003: Meldung: Aventis and Dermik Laboratories Delay Cream

Dermik Laboratories, the dermatology unit of Aventis Pharmaceuticals Inc. , announced today that, out of respect for the judicial process, Dermik will delay the U.S. launch of its new Vanamide(TM) urea cream, 40% product. The launch was originally scheduled for February 2003, but will be delayed pending a court decision on a request by Bradley Pharmaceuticals, Inc. for a preliminary injunction in the patent infringement lawsuit filed against Aventis and Dermik by Bradley in January 2003. The court is expected to rule on the request in the Second Quarter of 2003.

Bradley""s lawsuit alleges that the marketing and sale by Dermik and Aventis of the Vanamide(TM) urea cream product infringes three of Bradley""s patents relating to 40% urea dermatological compositions and their therapeutic uses. Bradley is seeking damages for the alleged infringement and an injunction against future infringements.

Aventis and Dermik believe that the Vanamide(TM) urea cream product, and its use in accordance with the product label, would be legally permissible. Aventis and Dermik will vigorously defend against the allegations in the lawsuit.

Statements in this news release other than historical information are forward-looking statements subject to risks and uncertainties. Actual results could differ materially depending on factors such as the availability of resources, the timing and effects of regulatory actions, the strength of competition, the outcome of litigation, and the effectiveness of patent protection. Additional information regarding risks and uncertainties is set forth in the current Aventis Annual Report on Form 20-F of Aventis on file with the Securities and Exchange Commission.

Contact:
Dermik Laboratories
222 South Central Avenue, Suite 400
St. Louis, MO 63105
Phone 800-678-7858, x3465. Fax 314-863-3631